Bora CDMO Bora CDMO

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Vico Therapeutics.

    Client Virtual Booth

    VICO THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Vico Therapeutics
    Netherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    BioScience Park BioPartner Building 1 J.H. Oortweg 21 2333 CH Leiden The Netherlands
    Telephone
    Telephone
    +31 71 2036800
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://vicotx.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/vico-therapeutics/
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vico Therapeutics Announces First Patient Dosed in Phase 1/2a Clinical Trial of VO659 in Huntington's Disease and Spinocerebellar Ataxia Types 1 and 3

    Details:

    VO659 is an antisense oligonucleotide (ASO) investigational therapy designed to target the CAG repeat expansion that causes all nine known polyglutamine diseases including huntington’s disease (HD), spinocerebellar ataxia type 1 (SCA1) and type 3 (SCA3).


    Lead Product(s): VO659

    Therapeutic Area: Genetic Disease Product Name: VO659

    Highest Development Status: Phase I/ Phase IIProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable April 03, 2023

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    US FDA grants VICO Therapeutics Orphan-Drug Designation for VO659, an Investigational Therapy for Huntington Disease

    Details:

    VICO’s lead antisense oligonucleotide product, VO659 is designed to suppress mutant proteins and slow or halt disease progression.


    Lead Product(s): VO659

    Therapeutic Area: Genetic Disease Product Name: VO659

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable July 29, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Development Update
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    European Commission grants Vico Therapeutics Orphan Drug Designation for VO659, an Investigational Therapy for Spinocerebellar Ataxia

    Details:

    The orphan designation was based on a positive opinion from the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP). Vico previously received orphan drug designation for VO659 in Huntington Disease.


    Lead Product(s): VO659

    Therapeutic Area: Neurology Product Name: VO659

    Highest Development Status: UndisclosedProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Not Applicable

    Deal Size: Not Applicable Upfront Cash: Not Applicable

    Deal Type: Not Applicable February 10, 2021

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Vico Therapeutics Raises $31 Million in Series A Financing Round

    Details:

    Vico will use this funding to further advance its late preclinical stage Antisense OligoNucleotides lead platform for the development of therapies for different forms of Spinocerebellar Ataxia (SCA) and Huntington Disease (HD) into first-in-human clinical trials in late 2021.


    Lead Product(s): Antisense Oligonucleotides

    Therapeutic Area: Genetic Disease Product Name: Undisclosed

    Highest Development Status: PreclinicalProduct Type: Large molecule

    Partner/Sponsor/Collaborator: Life Science Partners

    Deal Size: $31.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing July 30, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-m-2024-04-29

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search